Featured
Addressing Assessment and Access Issues for Rare Diseases
With the promise of more rare disease treatments on the horizon (particularly genetic treatments for hemophilia and sickle cell disease, which promise to be “one and done” therapies), their much higher per patient cost will create market access and other challenges to payers, providers, and patients.ISSUE HIGHLIGHTS
COLUMNS
HEOR Articles
The Role of Education in Shaping an Open-Source FutureBy the Numbers
HEOR & Rare DiseasesResearch Roundup
Research RoundupHEOR News
HEOR NewsEvents & Education
ISPOR Conferences and EventsLatest News
ISPOR Europe 2026 Plenaries Announced
Sep 30, 2026
New Study Sheds Light on QALY and Disability Debate
Sep 28, 2026
ISPOR Launches New HEOR Ambassadors Website
Sep 22, 2026
